Can novel delivery help Zynerba steal a march on cannabis giant GW?

11 April 2018

If it were ever doubted that cannabis-based therapies would one day occupy space in certain specialists’ armamentaria, that time has now certainly passed.

Asked whether a failure to take such therapies seriously had led to institutional resistance, Zynerba Pharmaceuticals (Nasdaq :ZYNE) chief executive Armando Anido tells The Pharma Letter: "If we had tried to do this five or six years ago, we would have seen more of that.”

He adds: “I give GW some credit because they've been at it for more than twenty years, and they blazed a path in this area. By showing data that the drug works, it helps get investors comfortable that it’s not mumbo-jumbo medicine."

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK